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Edited by Lukas HuberAbstract Epithelial cells can be manipulated to undergo apop-
tosis depending on the balance between pro-survival and apopto-
tic signals. We showed that TRAIL-induced apoptosis may be
diﬀerentially regulated by inhibitors of MEK ERK (U0126) or
PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29)
and TRAIL-resistant (SW620) human epithelial colon cancer
cells. U0126 or LY294002 signiﬁcantly enhanced TRAIL-in-
duced apoptosis in HT–29 cells, but not in SW620 cells. We re-
port a diﬀerent regulation of the level of an anti-apoptotic Mcl-1
protein under MEK/ERK or PI3K/Akt pathway inhibition and
suggest the mechanisms involved. A special attention was paid
to the role of the ERK1/2, Akt, and glycogen synthase kinase 3b.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The tumour necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL), a member of TNF family, is particularly
interesting for its unique properties to induce death of cancer
cells (including colon) while sparing most normal cells [1]. This
implies its use as a promising anti-cancer agent [2]. TRAIL in-
duces apoptosis via interacting with its cognate ‘death’ recep-
tors, DR4 and DR5, which in turn results in formation of
the death-inducing signalling complex (DISC), and caspase-8
processing [3,4]. Caspase-8 activation can then result in the
activation of two distinct pathways: a mitochondrial-indepen-
dent pathway (in type I cells) leading to direct caspase-3 acti-
vation and subsequent cleavage of death substrates, and/or a
mitochondrial-dependent pathway (in type II cells) involving
activation of the pro-apoptotic arm of the Bcl-2 family, and
the mitochondrial release of apoptogenic factors [5]. TRAIL
was shown to induce apoptosis in diﬀerent colon cancer cellAbbreviations: CK18, cytokeratin 18; DR, death receptor; ERK, ex-
tracellular signal-regulated kinase; FLIP, FLICE inhibitory protein;
GSK, glycogen synthase kinase; MMP, mitochondrial membrane
potential; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C;
PARP, poly(ADP)ribose polymerase; TRAIL, TNF-related apoptosis-
inducing ligand; TNF, tumour necrosis factor
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doi:10.1016/j.febslet.2006.11.004lines. Interestingly, during colorectal carcinogenesis, a marked
increase in sensitivity to the apoptotic eﬀects of TRAIL, asso-
ciated with progression from benign to malignant tumour type
has been reported [6]. For this study, we have used the human
colon adenocarcinoma cell line HT-29, which we previously
characterized as type II cells [7], and SW620 cells, which are
resistant to TRAIL-induced apoptosis, as models for colon
cancer.
Failure to undergo apoptosis in response to TRAIL treat-
ment may result in tumour resistance. Sensitivity towards
TRAIL-mediated apoptosis can be modulated at diﬀerent lev-
els in the TRAIL signalling pathway. Protein kinase-mediated
signalling has been described as an eﬀective way of directing
DR signals [8]. In contrast to regulation by inhibitory proteins
or TRAIL receptors, phosphorylation-based signalling may
occur without requirement of newly synthesized proteins. This
could be especially eﬀective under conditions when DR re-
sponses need to be rapidly modulated.
Besides its potential to selectively kill tumour cells, the phys-
iological role of TRAIL seems to be more complex. The ability
of TRAIL to promote survival and proliferation of non-cancer
cells has been reported [9]. Furthermore, in certain tumour
cells, simultaneous or consecutive TRAIL-induced activation
of apoptotic and pro-survival pathways has been demon-
strated [10]. The balance between these pathways is therefore
very important in determining the cell fate. Therefore, further
studies are necessary to examine the interaction between
TRAIL-induced apoptotic pathways and pro-survival path-
ways in order to predict the eﬀectiveness of TRAIL in cancer
therapy.
The mitogen-activated protein kinases (MAPKs) are serine–
threonine kinases that are activated by phosphorylation in re-
sponse to a variety of extracellular stimuli [11]. MAPKs play a
central role in the transduction of signals for growth and dif-
ferentiation and also act as important modulators of various
apoptosis-inducing signals. The extracellular signal-regulated
kinases (ERK1/2), activated by MEK1/2, phosphorylate and
modulate the function of many regulatory proteins. The pro-
tective eﬀect of ERK1/2 on DR-induced apoptosis has also
been reported [8].
PI3K/Akt is a major signalling pathway which mediates pro-
liferative signals in the intestinal epithelial cells in vitro and
in vivo [12]. In addition, this pathway is an important regulator
of cell diﬀerentiation and apoptosis [13]. Promotion of cell sur-
vival by the activation of this pathway occurs by inhibition of
pro-apoptotic or the induction of survival signals [14,15].
PI3K-mediated activation of Akt also results in inhibition ofblished by Elsevier B.V. All rights reserved.
6566 A. Vaculova´ et al. / FEBS Letters 580 (2006) 6565–6569glycogen synthase kinase 3b (GSK3b) by phosphorylation at
Ser 9. GSK3b has been implicated in fundamental processes
including cell survival, diﬀerentiation, apoptosis, metabolism,
transcriptional control, and oncogenesis [16].
The aim of this study was to investigate the role of the
MAPK/ERK and PI3K/Akt pathways in the regulation of
TRAIL-induced apoptosis of colon cancer cells and to study
the mechanisms involved.*
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Fig. 1. HT-29 cells (%) with cleaved CK18 (M30 cytodeath, FCM)
after pre-treatment with U0126 (10 lM, 45 min) or LY294002 (50 lM,
60 min) and treatment with TRAIL (100 ng/ml, 4 h). The results are
means of at least three independent experiments. Mann–Whitney test,
P < 0.05, (*) versus control, (+) versus TRAIL, (·) versus U0126 or
LY294002.
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SW6202. Materials and methods
2.1. Culture conditions
Human colon adenocarcinoma HT-29 and SW620 cells (ATCC,
Rockville, MD, USA) were cultured as described previously [7].
Twenty-four hours after seeding in McCoy’s medium with 5% fetal calf
serum, the cells were pre-treated with the MEK1/2 inhibitor—U0126
(10 lM), the PI3K inhibitor—LY294002 (50 lM) (Cell Signaling Tech-
nology), or vehicle (DMSO) alone for 45 or 60 min, respectively, and
then treated with TRAIL (human recombinant Killer TRAIL, 100 ng/
ml, kindly provided byL.Andeˇra, IMGPrague, CzechRepublic) for 4 h.
2.2. Cleavage of cytokeratin 18 (CK18)
The cells were stained with M30 cytodeath antibody (PEVIVA, Swe-
den) according to the manufacturer’s instructions and analysed
(1.5 · 104 cells per sample) using a ﬂow cytometer (FACSCalibur, Bec-
ton Dickinson, San Jose, CA, USA). Data were evaluated (CellQuest
software) as the percentage of the cells positive for M30 antibody
staining (apoptotic cells with speciﬁcally cleaved CK18).
2.3. Detection of mitochondrial membrane potential (MMP)
MMP was measured using ﬂow cytometer and TMRE as described
previously [7]. Evaluated data were expressed as a percentage of the
cells with decreased MMP.
2.4. Annexin V binding assay
The cells were washed with PBS and 2 · 105 cells per sample were
resuspended in a total volume of 100 ll of the incubation buﬀer
(10 mMHEPES/NaOH, pH 7.4, 140 mMNaCl, 5 mM CaCl2). Annex-
in-V-Fluos (0.5 ll per sample, Roche Diagnostics GmbH, Germany)
and propidium iodide (ﬁnal concentration 20 lg/ml) were added, and
the cell suspension was incubated for 10 min in the dark. Fluorescence
was then measured using ﬂow cytometer. The data were evaluated
(Cell Quest) and expressed as percentage of the cells positive for annex-
in-V and negative for propidium iodide (apoptotic cells).
2.5. Immunoblotting
The cell lysates were subjected to SDS–PAGE followed by immuno-
blotting as described previously [7]. The primary antibodies used were
anti-PARP (SC-7150, Santa Cruz Biotechnology), anti-Mcl-1 (M8434,
Sigma–Aldrich, Czech Republic), anti-cFLIP (#804-428, Alexis Bio-
chemicals), anti-caspase-8 (#9746), anti-phospho-ERK 1/2 (Thr202/
Tyr204, #9101), anti-ERK 1/2 (#9102), anti-phospho-Akt (Ser 472,
#9271), anti-Akt (#9272), anti-phospho-GSK3b (Ser 9, #9336) anti-
GSK3b (#9315) (Cell Signaling Technology) antibodies. As secondary
antibodies, we used horseradish peroxidase-labelled anti-mouse-IgG
(#NA931) or anti-rabbit-IgG (#NA934) (Amersham Biosciences,
Bucks., UK). An equal loading was veriﬁed using b-actin antibody
(A5441, Sigma).co
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Fig. 2. HT-29 and SW620 cells (%) with decreased MMP (TMRE,
FCM) after pre-treatment with U0126 (10 lM, 45 min) or LY294002
(50 lM, 60 min) and treatment with TRAIL (100 ng/ml, 4 h). The
results are means of at least three independent experiments. Mann–
Whitney test, P < 0.05, (*) versus control, (+) versus TRAIL, (·)
versus U0126 or LY294002.3. Results
3.1. Inhibition of MEK/ERK or PI3K/Akt resulted in
potentiation of TRAIL-induced apoptosis in HT-29 cells,
but not in SW620 cells
We demonstrated a signiﬁcant increase of the percentage of
HT-29 cells with speciﬁc CK18 cleavage after TRAIL + U0126
(38.5%) or TRAIL + LY294002 (50.2%) treatment compared
to TRAIL alone (22.3%). U0126 or LY294002 had no signiﬁ-cant eﬀect (1.4% or 2.6% of CK18 positive cells, respectively)
compared to untreated control (2%) (Fig. 1).
TRAIL induced a decrease of MMP in 14.5% of the cells.
These changes were further markedly potentiated by pre-treat-
ment with U0126 (26.6%) or LY294002 (34%). No signiﬁcant
eﬀects (4.8% for U0126, 3.8% for LY294002) compared to con-
trol (3.3%) were observed when inhibitors were used alone
(Fig. 2).
TRAIL induced a cleavage of pro-caspase-8, cFLIPL, and
poly(ADP)ribose polymerase (PARP) in HT-29 cells (Figs. 3
and 4). A strong potentiation of TRAIL-induced PARP cleav-
age (to its speciﬁc 89 kDa fragment) and a pro-caspase-8 cleav-
age (to its 41/43 kDa fragment) was detected in U0126- or
LY294002-pre-treated cells. Inhibitors alone had no eﬀect
(Figs. 3 and 4).
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Fig. 3. PARP, pro-caspase-8 and cFLIPL cleavage, Mcl-1 protein
level, phosphorylated and total ERK1/2 levels, and phosphorylated
GSK3b in HT-29 cells pre-treated with U0126 (10 lM, 45 min) and
then treated with TRAIL (100 ng/ml, 4 h), detected by Western
blotting. Results are representative of four independent experiments.
An equal loading was veriﬁed using b-actin antibody.
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Fig. 4. PARP and pro-caspase-8 cleavage, Mcl-1 protein level,
phosphorylated and total ERK1/2, Akt, and GSK3b levels in HT-29
cells pre-treated with LY294002 (50 lM, 60 min) and then treated with
TRAIL (100 ng/ml, 4 h), detected by Western blotting. Results are
representative of four independent experiments. An equal loading was
veriﬁed using b-actin antibody.
Table 1
Apoptotic SW620 cells (%) (annexin V binding assay, FCM) after pre-
treatment with U0126 (10 lM, 45 min) or LY294002 (50 lM, 60 min)
and treatment with TRAIL (100 ng/ml, 4 h)
Treatment Cells (%)
Control 1.9 ± 0.9
TRAIL 5.9 ± 2.7
U0126 2.9 ± 1.7
TRAIL + U0126 7.8 ± 4.5a
LY294002 2.4 ± 1.4
TRAIL + LY294002 8.4 ± 4.9a
The results are means of at least three independent experiments.
Mann–Whitney test, P < 0.05.
aVersus control.
A. Vaculova´ et al. / FEBS Letters 580 (2006) 6565–6569 6567In SW620 cells, TRAIL induced no signiﬁcant increase of
number of apoptotic cells as demonstrated by annexin V bind-
ing assay (Table 1). The cell sensitivity to apoptotic eﬀects of
TRAIL was further not signiﬁcantly changed after pre-treat-
ment with U0126 or LY294002. No signiﬁcant changes of
MMP were also apparent after any type of the treatment in
these cells (Fig. 2).
3.2. Basal and TRAIL-induced Mcl-1 protein levels are
diﬀerentially regulated under MEK/ERK or PI3K/Akt
pathway inhibition in HT-29 cells, but not in SW620 cells
Blockage of the MEK/ERK (U0126), but not PI3K/Akt
(LY294002) pathway resulted in a complete loss of basal
Mcl-1 protein level in HT-29 cells. Furthermore, TRAIL-
induced increase of Mcl-1 protein level was completely abol-
ished by U0126, but not by LY294002 (Figs. 3 and 4). In
TRAIL + LY294002-treated cells, an increase of Mcl-1 protein
level was demonstrated compared to TRAIL-treated cells
(Fig. 4). In SW620 cells, Mcl-1 protein was not lost after
U0126 treatment and no signiﬁcant diﬀerence was apparent
between U0126 and LY294002 eﬀects. TRAIL also did not
induce an increase in Mcl-1 protein level in SW620 cells
(Fig. 5).
3.3. TRAIL induced ERK1/2 activity in HT–29 cells
Compared to control, a signiﬁcant increase in ERK1/2 phos-
phorylation was demonstrated in TRAIL-treated HT-29 cells
(Figs. 3 and 4), but not in SW620 cells (not shown). Treatment
of HT-29 cells with U0126 completely inhibited basal as well as
TRAIL-induced ERK1/2 phosphorylation, without changes inco
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Fig. 5. Mcl-1 protein level in SW620 cells pre-treated with U0126
(10 lM, 45 min) or LY294002 (50 lM, 60 min) and then treated with
TRAIL (100 ng/ml, 4 h), detected by Western blotting. Results are
representative of three independent experiments. An equal loading was
veriﬁed using b-actin antibody.
6568 A. Vaculova´ et al. / FEBS Letters 580 (2006) 6565–6569ERK1/2 protein level (Fig. 3). On the other hand, a strong
potentiation of ERK1/2 phosphorylation was demonstrated
in cells treated with TRAIL + LY294002 compared to cells
treated with TRAIL alone (Fig. 4).
3.4. GSK3b is phosphorylated independently of PI3K/Akt in
HT-29 cells treated with TRAIL
Treatment of HT-29 cells with the PI3K inhibitor LY294002
completely inhibited Akt phosphorylation in LY294002-only
or TRAIL + LY294002-treated cells, without signiﬁcant
changes in Akt protein levels (Fig. 4). While an inhibition of
GSK3b phosphorylation was apparent in LY294002-only-
treated cells, a relatively high level of phosphorylated GSK3b
was detected in TRAIL + LY294002-treated cells. No signiﬁ-
cant changes in total GSK3b level were detected after any type
of treatment (Fig. 4).4. Discussion
The changes mediated by phosphorylation-based signalling
are very important for rapid modulation of the cellular sensi-
tivity to apoptosis. In our experiments, inhibition of MEK/
ERK or PI3K/Akt pathways by U0126 or LY294002, respec-
tively, resulted in potentiation of TRAIL-induced apoptosis
of HT-29 colon cancer cells. We demonstrated that TRAIL
can simultaneously activate both, apoptotic and pro-survival
pathways in these cells. Thus, the balance between these path-
ways is very important in determining the cell fate. On the
other hand, in SW620 cells, which are resistant to TRAIL, nei-
ther U0126 nor LY294002 were able to restore the cell sensitiv-
ity to the apoptotic eﬀect of this cytokine.
ERK1/2 signalling appears to be of particular importance as
it protects cells against apoptosis induced by a variety of stim-
uli. We demonstrated that complete inhibition of ERK1/2 did
not induce apoptosis of U0126-treated HT-29 cells. This sug-
gests that basal ERK1/2 activity is not essential for cell sur-
vival at the time studied, and that the ERK1/2 pathway may
become important for survival when activated by TRAIL.
Interestingly, TRAIL induced a strong phosphorylation of
ERK1/2 in HT–29 cells in our experiments. A speciﬁc inhibi-
tion of the ERK1/2 signalling pathway markedly sensitized
HT-29 colon cancer cells to TRAIL-induced apoptosis, which
was accompanied by a signiﬁcant potentiation of pro-caspase-
8 cleavage and a decrease of MMP. ERK1/2-mediated protec-
tion from TRAIL-induced apoptosis via inhibition of MMP
changes and decreased release of Smac/DIABLO has also been
demonstrated in melanoma cells [17].
At the level of mitochondria, anti-apoptotic Bcl-2 family
proteins have been shown to protect cells against TRAIL-in-
duced apoptosis. Among them, Mcl-1 protein is unique as it
can be rapidly induced and/or degraded, thus functioning as
an early-response protein and providing an acute protection
against apoptosis induction. Moreover, the dynamic regula-
tion of Mcl-1 protein level can be facilitated by its degradation
by the proteasome pathway [18] or caspase cleavage [19]. Mcl-
1 protein was responsible for TRAIL resistance in human
cholangiocarcinoma cells [20]. Interestingly, TRAIL induced
a strong up-regulation of Mcl-1 protein level in HT-29 cells
in our experiments. This eﬀect was completely abolished by
inhibition of the MEK/ERK pathway, which concomitantly
potentiated TRAIL-induced apoptosis. Thus, our results sug-gest that Mcl-1 may be involved in ERK1/2-mediated protec-
tion from TRAIL-induced apoptosis in HT-29 cells.
Mechanisms contributing to the regulation of Mcl-1 level are
controversially discussed and may include activation of the
MEK/ERK [21] and/or PI3K/Akt [22] pathway, depending
on the cell type.
We demonstrated that inhibition of the PI3K/Akt pathway
by LY294002 sensitized HT-29 cells to TRAIL-induced apop-
tosis, which was associated with an enhanced processing of
caspase-8, and cleavage of PARP and CK18. Inhibition of
PI3K by RNA interference also sensitized resistant colon can-
cer cells (KM20, KM12) to TRAIL-induced apoptosis through
the induction of TRAIL death receptors and caspase-8, -3 acti-
vation [23]. In our experiments, we conﬁrmed that Akt phos-
phorylation (activity) was inhibited by LY294002 which
resulted in dephosphorylation (activation) of GSK3b. Acti-
vated GSK3b is known to phosphorylate a broad range of sub-
strates including several transcription factors responsible for
regulation of genes involved in growth, survival and apoptosis.
Inhibition of PI3K/Akt/GSK-3 pathway with wortmannin has
been reported to increase TRAIL mRNA and protein expres-
sion in human colon cancer cell lines HT-29, HCT-116, and
CaCo-2 [24]. Of note, GSK3b was recently shown to promote
apoptosis by direct phosphorylation of Mcl-1 protein, leading
to its degradation by the ubiquitin-proteasome pathway, and
facilitating mitochondrial outer membrane permeabilization,
cytochrome c release, and apoptosis [18].
Interestingly, we demonstrated signiﬁcant diﬀerences in
GSK3b and ERK1/2 activities between LY294002- and
TRAIL + LY294002-treated cells. While no phosphorylated
GSK3b was detected in cells treated with LY294002 alone, a
phosphorylation (i.e. inactivation) of GSK3b was demon-
strated in TRAIL + LY294002-treated cells. As Akt activity
was completely inhibited by LY294002, our data suggest the
involvement of the protein kinase(s) other than Akt in the
inactivation of GSK3b in TRAIL-treated cells. In human neu-
roblastoma cells, protein kinase PKCd (activated by caspase-3
cleavage) was responsible for inactivation of GSK3b during
apoptosis [25]. We suggest that apoptosis-dependent activation
of other kinase(s) might lead to these changes at the level of
GSK3b. Furthermore, the existence of a cross-talk between
PI3K and ERK1/2 pathways with the potential for PI3K
pathway to act as an upstream activator of ERK1/2 has been
reported. GSK3b, acting through PKCd, has been demon-
strated as a negative regulator of ERK1/2 in HT-29 cells
[26]. This model is consistent with our results showing a strong
potentiation of ERK1/2 activity under GSK3b inhibition in
TRAIL + LY294002-treated HT-29 cells compared to cells
treated with LY294002 alone. Moreover, this potentiation of
ERK activity was accompanied by an increase in Mcl-1 pro-
tein level.
In SW620 cells, which were resistant to TRAIL (100 ng/ml)
in our experiments, U0126 or LY294002 were not eﬃcient to
overcome their resistance to TRAIL-induced apoptosis. Fur-
thermore, TRAIL did not induce any signiﬁcant increase in
Mcl-1 protein level or ERK1/2 activity in these cells. No signif-
icant diﬀerences in Mcl-1 protein level were also apparent be-
tween the cells treated with U0126 or LY294002.
Taken together, speciﬁc inhibitors of the MEK/ERK
(U0126) or PI3K/Akt (LY294002) pathways signiﬁcantly
enhanced TRAIL-induced apoptosis in HT-29 human colon
adenocarcinoma cells, but not in SW620 cells. We demon-
A. Vaculova´ et al. / FEBS Letters 580 (2006) 6565–6569 6569strated that, in addition to its pro-apoptotic activity, TRAIL
activated pro-survival pathways—stimulated ERK1/2 phos-
phorylation and increased an anti-apoptotic Mcl-1 protein le-
vel in HT-29 cells. These eﬀects were completely abolished by
U0126, which concomitantly potentiated TRAIL-induced
apoptosis. We suggest that Mcl-1 is involved in ERK1/2-med-
iated protection from TRAIL-induced apoptosis in these cells.
None of the described eﬀects was apparent in TRAIL resistant
SW620 cells. Furthermore, PI3K/Akt-independent phosphory-
lation (inactivation) of GSK3b was apparent in HT-29 cells
treated with TRAIL. This was associated with a signiﬁcant
potentiation of ERK1/2 phosphorylation and an increase in
Mcl-1 protein level. Thus, we report a diﬀerent regulation of
the level of this anti-apoptotic protein under MEK/ERK and
PI3K/Akt pathway inhibition. We also suggest a possible role
of crosstalk between MEK/ERK and PI3K/Akt pathways in
regulation of TRAIL-induced apoptosis. To conclude, we
showed that TRAIL-induced apoptosis may be diﬀerentially
regulated by inhibitors of MEK/ERK or PI3K/Akt pathway
in TRAIL-sensitive and TRAIL-resistant colon cancer cells.
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